Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

被引：0
|
作者：
O. Katopodis
J. Souglakos
E. Stathopoulos
A. Christopoulou
E. Kontopodis
A. Kotsakis
K. Kalbakis
N. Kentepozidis
A. Polyzos
D. Hatzidaki
V. Georgoulias
机构：
[1] Hellenic Oncology Research Group (HORG),
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Gemcitabine; Oxaliplatin; Erlotinib; Phase II trial; Pancreas;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：333 / 340
页数：7
相关论文
共 50 条
  • [21] Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation
    Fountzilas, George
    Bobos, Mattheos
    Kalogera-Fountzila, Anna
    Xiros, Nikolaos
    Murray, Samuel
    Linardou, Helena
    Karayannopoulou, Georgia
    Koutras, Angelos K.
    Bafaloukos, Dimitrios
    Samantas, Epaminondas
    Christodoulou, Christos
    Economopoulos, Theofanis
    Kalogeras, Konstantine T.
    Kosmidis, Paris
    CANCER INVESTIGATION, 2008, 26 (08) : 784 - 793
  • [22] Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Chul
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Seong Kyu
    Lee, Yun Nah
    Moon, Jong Ho
    YONSEI MEDICAL JOURNAL, 2021, 62 (08) : 671 - 678
  • [23] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [24] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
  • [25] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [26] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [27] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Petrioli, Roberto
    Roviello, Giandomenico
    Fiaschi, Anna Ida
    Laera, Letizia
    Marrelli, Daniele
    Roviello, Franco
    Francini, Edoardo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 683 - 690
  • [28] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Roberto Petrioli
    Giandomenico Roviello
    Anna Ida Fiaschi
    Letizia Laera
    Daniele Marrelli
    Franco Roviello
    Edoardo Francini
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 683 - 690
  • [29] Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study
    Schneider, BP
    Ganjoo, KN
    Seitz, DE
    Picus, J
    Fata, F
    Stoner, C
    Calley, C
    Loehrer, PJ
    ONCOLOGY, 2003, 65 (03) : 218 - 223
  • [30] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    Feliu, J.
    Borrega, P.
    Leon, A.
    Lopez-Gomez, L.
    Lopez, M.
    Castro, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Martinez, V.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 215 - 221
12345